Symptomatic therapy in multiple sclerosis

Therapeutic Advances in Neurological Disorders

Volumn 4, Issue 2, 2011, Pages 83-98

  Frohman, Teresa C ^a   Castro, Wanda ^a   Courtney, Ardith ^a   Ortstadt, Jeffrey ^a   Davis, Scott L ^a   Logan, Diana ^a   Abraham, Thomas ^a   Abraham, Jaspreet ^a   Remington, Gina ^a   Treadaway, Katherine ^a   Graves, Donna ^a   Greenberg, Benjamin ^a   Shah, Anjali ^a   Hart, John ^b   Stuve, Olaf ^c   Lemack, Gary ^a   Frohman, Elliot M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

fatigue; multiple sclerosis; neurogenic bowel and bladder; spasticity; symptomatic therapy; visual symptoms

Indexed keywords

4 AMINOPYRIDINE; ACETYLCARNITINE; AMANTADINE; AMPYRA; ANTICONVULSIVE AGENT; BACLOFEN; BENZODIAZEPINE; BOTULINUM TOXIN; CANNABIS; CLONAZEPAM; CLONIDINE; CORTICOSTEROID; CYPROHEPTADINE; DALFAMPRIDINE; DANTROLENE; DIAZEPAM; ETIRACETAM; GABAPENTIN; HARKOSERIDE; HYPNOTIC SEDATIVE AGENT; INTERFERON; MEMANTINE; MODAFINIL; NAPROXEN; NARCOTIC ANALGESIC AGENT; PHENOL; PIRACETAM; POTASSIUM; TIZANIDINE; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL DISCOMFORT; ABNORMAL SENSATION; ACROCYANOSIS; ANKLE FOOT ORTHOSIS; ANOREXIA; ATAXIA; AUTONOMIC DYSFUNCTION; BALANCE DISORDER; BENIGN PAROXYSMAL POSITIONAL VERTIGO; BLOOD PRESSURE; BRACE; BRADYCARDIA; BRAIN DEPTH STIMULATION; BREATHING DISORDER; COGNITIVE DEFECT; COMPRESSION GARMENT; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DYSPHAGIA; DYSTONIA; ECG ABNORMALITY; EDEMA; EYE MOVEMENT DISORDER; FATIGUE; FLATULENCE; GAIT; HAND MOVEMENT; HUMAN; HYPOTENSION; INCREASED APPETITE; INTELLECTUAL IMPAIRMENT; KINESIOTHERAPY; LIVER TOXICITY; MEMORY DISORDER; MOOD DISORDER; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROGENIC BLADDER; NEUROGENIC BOWEL; NEUROLEPTIC MALIGNANT SYNDROME; NEUROPATHIC CAUSALGIA; NEUROPATHIC PAIN; NYSTAGMUS; OPTIC NEURITIS; ORTHOSIS; ORTHOSTATIC HYPOTENSION; OVERACTIVE BLADDER; PELVIC FLOOR MUSCLE TRAINING; PENDULAR NYSTAGMUS; PERIPHERAL NEUROPATHY; PHYSICAL ACTIVITY; POSTURAL INSTABILITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN DISEASE; SLEEP DISORDER; SLURRED SPEECH; SOMNOLENCE; SPASTICITY; SPEECH DISORDER; SPEECH THERAPY; SYMPTOMATOLOGY; SYNCOPE; TACHYCARDIA; TINGLING SENSATION; TREMOR; VASOSPASM; VISUAL DISORDER; VITAMIN SUPPLEMENTATION; VOMITING; WALKING DIFFICULTY; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 79955990115     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285611400658     Document Type: Review

References (80)

1. Araki I. Matsui M. Ozawa K. Takeda M. Kuno S. (2003) Relationship of bladder dysfunction to lesion site in multiple sclerosis. J Urol 169: 1384–1387.
2. Balcer L.J. (2006) Clinical practice. Optic neuritis. N Engl J Med 354: 1273–1280.
3. Bamer A.M. Johnson K.L. Amtmann D. Kraft G.H. (2008) Prevalence of sleep problems in individuals with multiple sclerosis. Mult Scler 14: 1127–1130.
4. Barnes M.P. Kent R.M. Semlyn J.K. McMullen L.M. (2003) Spasticity in multiple sclerosis. Neurorehabil Neural Repair 17: 66–70.
5. Beck A.T. Ward C.H. Mendelson M. Mock J. Erbaugh J. (1961) An inventory for measuring depression. Arch Gen Psychiatry 4: 561–571.
6. Beck R.W. Cleary P.A. Anderson M.M. Jr. Keltner J.L. Shults W.T. Kaufman D.I. et al (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 326: 581–588.
7. Beck R.W. Trobe J.D. Moke P.S. Gal R.L. Xing D. Bhatti M.T. et al (2003) High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 121: 944–949.
8. Benedict R. Cookfair D. Gavett R. Gunther M. Munschauer F. Garg N. et al (2006) Validity of the minimal assessment of cognitive function in multiple sclerosis. J Int Neuropsychol Soc 12: 549–558.
9. Borello-France D. Leng W. O'Leary M. Xavier M. Erickson J. Chancellor M.B. et al (2004) Bladder and sexual function among women with multiple sclerosis. Mult Scler 10: 455–461.
10. Brady C.M. DasGupta R. Dalton C. Wiseman O.J. Berkley K.J. Fowler C.J. (2004) An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 10: 425–433.
11. Buysse D.J. Hall M.L. Strollo P.J. Kamarch T.W. Owens J. Lee L. et al (2008) Relationships between the Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and clinical / polysomnographic measures in a community sample. J Clin Sleep Med 4: 563–571.
12. Campbell J.D. Gries K.S. Watanabe J.H. Ravelo A. Dmochowski R.R. Sullivan S.D. (2009) Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: A review of published evidence. BMC Urol 9: 18–19.
13. Chancellor M.B. Blaivas J.G. (1994) Urological and sexual problems in multiple sclerosis. Clin Neurosci 2: 189–195.
14. Christodoulou C. Melville P. Scherl W. MacAllister W. Elkins L. Krupp L. (2006) Effects of donepezil on memory and cognition in multiple sclerosis. J Neurol Sci 245: 127–136.
15. Chung F. Yegneswaran B. Liao P. Chung S.A. Vairavanatghan S. Khejaehdehl A. et al (2008) Validation of the Berlin questionnaire and American Society of Anesthesiologists checklist as screening tools for obstructive sleep apnea in surgical patients. Anesthesiology 108: 822–830.
16. Clark C.M. Fleming J.A. Li D. Oger J. Klonoff H. Paty D. (1992) Sleep disturbance, depression, and lesion site in patients with multiple sclerosis. Arch Neurol 49: 641–643.
17. Correale J. Ysrraelit M.C. Gait M.I. (2009) Immunomodulatory effects of Vitamin D multiple sclerosis. Brain 132: 1146–1160.
18. DasGupta R. Fowler C.J. (2003) Bladder, bowel and sexual dysfunction in multiple sclerosis: Management strategies. Drugs 63: 153–166.
19. Davis S.L. Wilson T.E. White A.T. Frohman E.M. (2010) Thermoregulation in multiple sclerosis. J Appl Physiol 109: 1531–1537.
20. de Luca J. Chelune G. Tulsky D. Lengenfelder J. Chiaravalloti N. (2004) Is speed of processing or working memory the primary information processing deficit in multiple sclerosis? J Clin Exp Neuropsychol 26: 550–562.
21. Feldman M. (2006) Sleisenger & Fordtran's Gastrointestinal and Liver Disease, 8th. Saunders Elsevier:Philadelphia, PA.
22. Fischer J. (2001) Cognitive impairments in multiple sclerosis. In: Ed. Cook S.D. (ed.). Handbook of Multiple Sclerosis, Marcel Dekker: New York, 233–256.
23. Fleming W.E. Pollak C.P. (2005) Sleep disorders in multiple sclerosis. Semin Neurol 25: 64–68.
24. Frohman E.M. Frohman T.C. Zee D.S. McColl R. Galetta S. (2005) The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 4: 111–121.
25. Frohman E.M. Kramer P.D. Dewey R.B. Kramer L. Frohman T.C. (2003) Benign paroxysmal positioning vertigo in multiple sclerosis: diagnosis, pathophysiology and therapeutic techniques. Mult Scler 9: 250–255.
26. Frohman E.M. Shah A. Eggenberger E. Metz L. Zivadinov R. Stuve O. (2007) Corticosteroids for multiple sclerosis: I. Application for treating exacerbations. Neurotherapeutics 4: 618–626.
27. Frohman E.M. Zhang H. Dewey R.B. Hawker K.S. Racke M.K. Frohman T.C. (2000) Vertigo in MS: Utility of positional and particle repositioning maneuvers. Neurology 55: 1566–1569.
28. Goodman A.D. Brown T.R. Edwards K.R. Krupp L.B. Schapiro R.T. Cohen R. et al (2010) A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 68: 494–502.
29. Green B.G. Martin S. (2000) Clinical assessment of sildenafil in the treatment of neurogenic male sexual dysfunction: After the hype. NeuroRehabilitation 15: 101–105.
30. Gutierrez G.M. Chow J.W. Tillman M.D. McCoy S.D. Castellano V. White L.J. (2005) Resistance training improves gait kinematics in persons with multiple sclerosis. Arch Phys Med Rehabil 86: 1824–1829.
31. Handunnetthi L. Ramagopalan S.V. Ebers G.C. (2010) Multiple sclerosis, vitamin D, and HLA-DRB1*15. Neurology 74: 1905–1910.
32. Haselkorn J.K. Balsdon R.C. Fry W.D. (2005) Overview of spasticity management in multiple sclerosis. Evidence-based management strategies for spasticity treatment in multiple sclerosis. J Spinal Cord Med 2: 167–199.
33. Holick M.F. (2007) Vitamin D deficiency. N Engl J Med 357: 266–281.
34. Hulter B.M. Lundberg P.O. (1995) Sexual function in women with advanced multiple sclerosis. J Neurol Neurosurg Psychiatry 59: 83–86.
35. Johns M.W. (1991) A new method for measuring daytime sleepiness – the Epworth Sleepiness Scale. Sleep 14: 540–545.
36. Karsenty G. Denys P. Amarenco G. de Seze M. Gam È.X. Haab F. et al (2008) Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity / neurogenic overactive bladder: a systematic literature review. Eur Urol 53: 275–287.
37. Kato T. Kanbayashi T. Yamamoto K. (2003) Hypersomnia and low CSF hypocretin-1 (orexin-A) concentration in a patient with multiple sclerosis showing bilateral hypothalamic lesions. Intern Med 42: 743–745.
38. Keltner J.L. Johnson C.A. Spurr J.O. Beck R.W. (1993) Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Arch Ophthalmol 111: 231–234.
39. Kragt J.J. Hoogervorst E.L. Uitdehaag B.M. Polman C.H. (2004) Relation between objective and subjective measures of bladder dysfunction in multiple sclerosis. Neurology 63: 1716–1718.
40. Krupp L. Christodoulou C. Melville P. Scherl W.F. MacAllister W.S. Elkins L.E. (2004) Donezepil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 63: 1579–1585.
41. Lapierre Y. Hum S. (2007) Treating fatigue. Int MS J 14: 64–71.
42. Lienau F.S. Fullgraf H. Moser A. Feuerstein T.J. (2007) Why do cannabinoids not show consistent effects as analgetic drugs in multiple sclerosis? Eur J Neurol 14: 1162–1169.
43. Lincoln N. Dent A. Harding J. Weyman N. Nicholl C. Blumhardt L.D. et al (2002) Evaluation of cognitive assessment and cognitive intervention for people with people with MS. J Neurol Neurosurg Psychiatry 72: 93–98.
44. Litwiller S.E. Frohman E.M. Zimmern P.E. (1999) Multiple sclerosis and the urologist. J Urol 161: 743–757.
45. Manconi M. Ferini-Strambi L. Filippi M. Bonnani E. Iudice A. Murri L. et al (2008) Multicenter case–control study on restless legs syndrome in multiple sclerosis: the REMS study. Sleep 31: 944–952.
46. Mattson D. Petrie M. Srivastava D.K. McDermott M. (1995) Multiple sclerosis. Sexual dysfunction and its response to medications. Arch Neurol 52: 862–868.
47. Merlino G. Fratticci L. Lenchig C. Valente M. Cargnelutti D. Picello M. et al (2009) Prevalence of ‘poor sleep’ among patients with multiple sclerosis: An independent predictor of mental and physical status. Sleep Med 10: 26–34.
48. Morrow S. Kaushik T. Zarevics P. Erlanger D. Bear M.F. Munschauer F.E. et al (2009) The effects of L-amphetamine sulfate on cognition in MS patients: Results of a randomized controlled trial. J Neurol 256: 1095–1102.
49. Mutuay F.K. Demir R. Ozyilmaz S. Caglar A.T. Altinatas A. Gurses H.N. (2007) Breathing-enhanced upper extremity exercises for patients with multiple sclerosis. Clin Rehab 21: 595–602.
50. Newman M.A. Dawes H. van den Berg M. Wade D.T. Burridge J. Izadi H. (2007) Can aerobic treadmill training reduce the effort of walking and fatigue in people with multiple sclerosis: A pilot study. Mult Scler 13: 113–119.
51. O'Connor A.B. Schwid S.R. Herrmann D.N. Markman J.D. Dworkin R.H. (2008) Pain associated with multiple sclerosis: Systematic review and proposed classification. Pain 137: 96–111.
52. Oka Y. Kanbayashi T. Mezaki T. Iseki K. Matsubayashi J. Murakami G. et al (2003) Decreased CSF hypocretin-1 level in hypersomnia with bilateral hypothalamic lesion. Sleep 26: A349–A349.
53. Olggiati R. Burgunder J.M. Mumenthaler M. (1988) Increased energy cost of walking in multiple sclerosis: Effect of spasticity, ataxia, and weakness. Arch Phys Med Rehabil 69: 846–849.
54. Optic Neuritis Study Group. (2007) Visual function 15 years after optic neuritis: A final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology 115: 1079–1082.
55. Plazzi G. Montagna P. (2002) Remitting REM sleep behavior disorder as the initial sign of multiple sclerosis. Sleep Med 3: 437–439.
56. Ramagopalan S.V. Hanwell H.E. Giovannoni G. Knappskog P.M. Nyland H.I. Myhr K.M. et al (2010) Vitamin D-dependent rickets, HLA-DRB1, and the risk of multiple sclerosis. Arch Neurol 67: 1034–1035.
57. Rampello A. Franceschini M. Piepoli M. Antenucci R. Lenti G. Olivieri D. et al (2007) Effect of aerobic training on walking capacity and maximal exercise tolerance in patients with multiple sclerosis: A randomized crossover controlled study. Phys Ther 87: 545–555, discussion 555–559.
58. Rao S.M. Grafman J. DiGiulio D. Mittenberg W. Bernardin L. Leo G.J. et al (1993) Memory dysfunction in multiple sclerosis: Its relation to working memory, semantic encoding, and implicit learning. Neuropsychology 7: 364–374.
59. Rasova K. Brandejsky P. Havrdova E. Zalisova M. Rexova P. (2005) Spiroergometric and spirometric parameters in patients with multiple sclerosis: Are there any links between these parameters and fatigue, depression, neurological impairment, disability, handicap and quality of life in multiple sclerosis? Mult Scler 11: 213–221.
60. Rasova K. Havrdova E. Brandejsky P. Zalisova M. Foubikova B. Martinkova P. (2006) Comparison of the influence of different rehabilitation programmes on clinical, spirometric and spiroergometric parameters in patients with multiple sclerosis. Mult Scler 12: 227–234.
61. Rizzo M.A. Hadjimichael O.C. Preiningerova J. Vollmer T.L. (2004) Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 10: 589–595.
62. Sabapathy N.M. Minahan C.L. Turner G.T. Broadley S.A. (2011) Comparing endurance- and resistance-exercise training in people with multiple sclerosis: A randomized pilot study. Clin Rehabil 25: 14–24.
63. Sadovnick A.D. Ebers G.C. (1993) Epidemiology of multiple sclerosis: A critical overview. Can J Neurol Sci 20: 17–29.
64. Schmidt E.Z. Hofmann P. Niederwieser G. Kapfhammer H.P. Bonelli R.M. (2005) Sexuality in multiple sclerosis. J Neural Transm 112: 1201–1211.
65. Schulz K.H. Gold S.M. Witte J. Bartsch K. Lang U.E. Hellweg R. et al (2004) Impact of aerobic training on immune-endocrine parameters, neurotrophic factors, quality of life and coordinative function in multiple sclerosis. J Neurol Sci 225: 11–18.
66. Sioka C. Kyritsis A.P. Fotopoulos A. (2009) Multiple sclerosis, osteoporosis, and vitamin D. J Neurol Sci 287: 1–6.
67. Starck M. Albrecht H. Pollmann W. Straube A. Dieterich M. (1997) Drug therapy for acquired pendular nystagmus in multiple sclerosis. J Neurol 244: 9–16.
68. Strupp M. Brandt T. (2006) Pharmacological advances in the treatment of neuro-otological and eye movement disorders. Curr Opin Neurol 19: 33–40.
69. Syndulko K. Jafari M. Woldanski A. Baumhefner R.W. Tourtellotte W.W. (1996) Effects of temperature in multiple sclerosis: A review of literature. J Neurol Rehabil 10: 23–34.
70. Tachibana N. Howard R.S. Hirsch N.P. Miller D.H. Moseley I.F. Fish D. (1994) Sleep problems in multiple sclerosis. Eur Neurol 34: 320–323.
71. Terre-Boliart R. Orient-Lopez F. Guervara-Espinosa D. Ramon-Roa S. Bernabeu-Guitart M. Clave-Civit P. (2004) Oropharyngeal dysphagia in patients with multiple sclerosis. Rev Neurol 39: 707–710.
72. Tomassini V. Pozzilli C. Onesti E. Pasqualetti P. Marinelli F. Pisani A. et al (2004) Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: Results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci 218: 103–108.
73. Traish A.M. Goldstein I. Kim N.N. (2007) Testosterone and erectile function: From basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction. Eur Urol 52: 54–70.
74. Vahtera T. Haaranen M. Viramo-Koskela A.L. Ruutiainen J. (1997) Pelvic floor rehabilitation is effective in patients with multiple sclerosis. Clin Rehabil 11: 211–219.
75. Winge K. Rasmussen D. Werdelin L.M. (2003) Constipation in neurological diseases. J Neurol Neurosurg Psychiatry 74: 13–19.
76. Wunderlin B.W. Kesseling J. Ginzler H. (1997) Fatigue in multiple sclerosis is not due to sleep apnoea. Eur J Neurol 4: 72–78.
77. Yang C.C. Bowen J.R. Kraft G.H. Uchio E.M. Kromm B.G. (2000) Cortical evoked potentials of the dorsal nerve of the clitoris and female sexual dysfunction in multiple sclerosis. J Urol 164: 2010–2013.
78. Yang C.C. Bowen J.D. Kraft G.H. Uchio E.M. Kromm B.G. (2001) Physiologic studies of male sexual dysfunction in multiple sclerosis. Mult Scler 7: 249–254.
79. Zivadinov R. Zorzon M. Locatelli L. Stival B. Monti F. Nasuelli D. et al (2003) Sexual dysfunction in multiple sclerosis: A MRI, neurophysiological and urodynamic study. J Neurol Sci 210: 73–76.
80. Zorzon M. Zivadinov R. Bosco A. Bragadin L.M. Moretti R. Bonfigli L. et al (1999) Sexual dysfunction in multiple sclerosis: A case–control study. I. Frequency and comparison of groups. Mult Scler 5: 418–427.